Table 4.
Advanced fibrosis among NAFLD individuals with metabolic abnormalities€
| Moderate or severe hepatic steatosis individuals |
Percentage with advanced fibrosis % (S.E.) |
||
|---|---|---|---|
| No | Indeterminate | Yes | |
| All (n = 1468) | 59.8% (2.1) | 33.6% (1.8) | 6.6% (0.9) |
| Metabolic syndrome (n = 804) | 43.0% (3.5) | 45.9% (3.2) | 11.1% (1.7) |
| Three abnormalities (n = 373) | 52.4% (4.4) | 40.8% (4.4) | 6.8% (2.2) |
| Four abnormalities (n = 287) | 43.5% (5.3) | 49.3% (5.2) | 7.2% (1.7) |
| Five abnormalities (n = 144) | 17.6% (5.1) | 52.1% (4.9) | 30.3% (4.5) |
| Increased WC (n = 1038) | 49.9% (2.6) | 41.5% (2.2) | 8.7% (1.3) |
| IFG/Diabetes (n = 556) | 27.7% (3.8) | 53.7% (3.4) | 18.6% (2.8) |
| High Triglyceride level (n = 752) | 54.2% (3.8) | 38.0% (3.4) | 7.7% (1.1) |
| Low HDL level (n = 767) | 54.8% (3.0) | 37.2% (2.7) | 8.0% (1.1) |
| High BP (n = 713) | 44.8% (2.9) | 44.3% (2.8) | 10.9% (1.7) |
Abbreviations: NAFLD – nonalcoholic fatty liver disease, WC – waist circumference, IFG – impaired fasting glucose, S.E. – standard error of percentage
€
not included if missing value for age, body mass index, impaired fasting glucose/diabetes, platelet count, albumin, aspartate aminotransferase, or alanine aminotransferase